Lung Cancer Clinical Trial
Official title:
Assessing the Magnitude and Potential Impact of Respiration-Induced Three-Dimensional Motion of Tumors and Normal Tissues Using Four-Dimensional CT Technology
Primary Objectives:
- To collect accurate and reliable respiration-induced anatomic structure motion data
using four-dimensional (4-D) imaging technology.
- To analyze these data to study respiration-induced variations and patterns in
variations of positions, shapes and volumes of tumors and normal anatomic structures in
the thorax and abdomen over a breathing cycle, from one breathing cycle to the next,
day-to-day and over the course of radiotherapy.
- To assess dosimetric and potential clinical consequences of respiratory motion in the
current practice of radiotherapy through preclinical treatment simulation (treatment
planning) studies.
- To quantify the potential consequences of explicitly accounting for respiration-induced
motion on dose distributions and outcome (tumor control probabilities and normal tissue
complication probabilities) through preclinical treatment simulation studies.
Secondary Objectives:
- To investigate the feasibility of using patient training to regulate patient breathing
and improve the quality of images and to stratify patients for their eligibility for
respiratory-correlated imaging and radiotherapy and for the implementation of various
strategies for mitigation of respiratory-induced motion.
- To assess the degree of correlation of the marker (or internal anatomic structure such
as diaphragm) being tracked as surrogate of breathing with the motion of structures and
the intra-fraction and inter-fraction reproducibility of such correlation.
- To quantify the effects of radiation therapy on the patterns of respiratory-induced
motion of structures through preclinical treatment simulation studies.
- To compare various strategies for either accounting for or mitigating
respiration-induced motion in the planning and delivery of radiation therapy.
You will be taking part in this study while you receive radiotherapy treatment for your
tumor.
You will be trained to breathe in a certain way that will help the study staff to perform
motion CT scans. You may be asked to breathe normally, or hold your breath, or breathe while
following a TV monitor. On the monitor, you will be viewing your breathing trace and using
the trace to regulate your breathing as instructed by the health professionals.
While you are in the right position for the scan, the study staff will perform motion CT
scans. A total of up to 12 scanning sessions will be held over your entire course of
radiotherapy. The first scanning session may last from 45 to 90 minutes, but later sessions
may be shorter. These CT scans are separate from the routine CT scans you may receive as
part of regular radiation treatment planning.
Scans may be taken at various periods of time. The scans can be taken one right after
another, or with a short separation between them. One scan can be taken on the first day,
and the next scan on the next day, or up to a week later.
By looking at the scans, researchers can better understand how your tumor and other organs
move from breath to breath, from day to day, and from week to week.
This is an investigational study. About 210 patients with the same tumor location as you
will take part in this study. All will be enrolled at M. D. Anderson.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|